New Clinical Data On Ariad Pharmaceuticals, Inc. Novel mTOR Inhibitor, AP23573, To Be Presented At Upcoming Oncology Meetings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that clinical investigators from leading cancer centers will present, for the first time, data from three clinical trials of the Company’s novel mTOR inhibitor, AP23573, at the 17th AACR-NCI-EORTC (ANE) International Conference on “Molecular Targets and Cancer Therapeutics” in Philadelphia, Pennsylvania, November 14 to 18, 2005. Data from the sarcoma trial will also be presented at the 11th Annual Connective Tissue Oncology Society (CTOS) Meeting in Boca Raton, Florida, November 19 to 21, 2005.

MORE ON THIS TOPIC